查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1719126

氣喘治療市場－全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、給藥方式、配銷通路、地區和競爭情況細分，2020 年至 2030 年

Asthma Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Mode of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球氣喘治療市場價值為 278.4 億美元，預計到 2030 年將達到 364.7 億美元，預測期內複合年成長率為 4.58%。由於氣喘盛行率上升、醫療保健投資增加以及先進療法的研發力度加大，市場正在不斷擴大。氣喘仍然是全球主要的公共衛生問題，特別是在美國這樣的國家，氣喘的負擔使得對有效治療的需求龐大。藥物輸送系統的技術創新（例如智慧吸入器和霧化器）以及生物療法的日益普及正在改變氣喘的管理。生物製劑治療可為重症病例提供有針對性的干涉，改善治療效果並減少住院。這些進步，加上對以患者為中心和精準醫療的關注，預計將推動全球氣喘治療領域的持續成長。

市場概覽
預測期 2026-2030
2024年市場規模 278.4億美元
2030年市場規模 364.7億美元
2025-2030 年複合年成長率 4.58%
成長最快的領域 網路藥局
最大的市場 北美洲

關鍵市場促進因素

加大研發投入

主要市場挑戰

先進療法成本高昂

主要市場趨勢

數位健康科技的整合

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球氣喘治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依藥物類別（短效BETA-激動劑 (SABA)、長效BETA-激動劑 (LABA)、吸入性皮質類固醇 (ICS)、白三烯調節劑、免疫調節劑、複方藥物、其他）
    • 依給藥方式（吸入器、霧化器、口服藥物）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房、其他）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：北美氣喘治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲氣喘治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太氣喘治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美洲氣喘治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲氣喘治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • GlaxoSmithKline, Plc
  • AstraZeneca Plc
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim Gmbh
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi SA
  • Roche Holding AG
  • Regeneron Pharmaceutical Inc.
  • Pfizer Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 15533

The Global Asthma Treatment Market was valued at USD 27.84 billion in 2024 and is projected to reach USD 36.47 billion by 2030, growing at a CAGR of 4.58% during the forecast period. The market is expanding due to the rising prevalence of asthma, increased healthcare investment, and growing R&D initiatives focused on advanced therapeutics. Asthma remains a major public health concern globally, particularly in countries like the United States, where its burden has created significant demand for effective treatments. Technological innovations in drug delivery systems-such as smart inhalers and nebulizers-and the growing availability of biologic therapies are transforming asthma management. Biologic treatments offer targeted intervention for severe cases, improving outcomes and reducing hospitalizations. These advancements, along with the focus on patient-centric and precision medicine, are expected to drive continued growth in the global asthma treatment landscape.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 27.84 Billion
Market Size 2030USD 36.47 Billion
CAGR 2025-20304.58%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Key Market Drivers

Increasing Investment in Research and Development

Substantial investment in R&D is a key driver of innovation in the asthma treatment market. With asthma being a complex, chronic condition, pharmaceutical companies and health organizations are prioritizing the development of new drugs and therapies to meet unmet needs. In the U.S., the National Institutes of Health (NIH) allocates over USD 100 million annually for asthma research, supporting advancements in diagnostics, treatment modalities, and prevention strategies. These investments contribute to breakthroughs in biologics, combination therapies, and personalized medicine approaches that enhance treatment effectiveness and patient outcomes. Furthermore, advancements in drug delivery devices and digital health solutions are improving disease monitoring and self-management.

Key Market Challenges

High Cost of Advanced Therapies

A major barrier in the global asthma treatment market is the high cost of biologic therapies used to treat severe asthma. These treatments, such as monoclonal antibodies, can cost thousands of dollars annually per patient, limiting access in low- and middle-income countries and placing strain on healthcare budgets even in developed regions. Limited insurance coverage and inconsistent reimbursement policies further exacerbate this issue, often resulting in delays or non-adherence to prescribed therapies. While biologics are effective, the associated costs can hinder widespread adoption, and addressing this financial barrier will be crucial for equitable access to advanced asthma treatments.

Key Market Trends

Integration of Digital Health Technologies

The increasing integration of digital technologies is reshaping asthma management. Tools such as mobile apps, wearable devices, and smart inhalers are enabling patients to track symptoms, monitor environmental triggers, and ensure medication adherence in real time. Smart inhalers equipped with sensors send usage data to connected devices, allowing both patients and healthcare providers to assess therapy effectiveness and make timely adjustments. These innovations support personalized asthma management, reduce flare-ups, and decrease hospital visits. As healthcare moves toward remote monitoring and data-driven decision-making, digital health technologies are expected to play a central role in asthma care delivery.

Key Market Players

  • GlaxoSmithKline, Plc
  • AstraZeneca Plc
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim GmbH
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi SA
  • Roche Holding AG
  • Regeneron Pharmaceutical Inc.
  • Pfizer Inc.

Report Scope:

In this report, the Global Asthma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Asthma Treatment Market, By Drug Class:

  • Short-Acting Beta-Agonists (SABA)
  • Long-Acting Beta-Agonists (LABA)
  • Inhaled Corticosteroids (ICS)
  • Leukotriene Modifiers
  • Immunomodulators
  • Combination Drugs
  • Others

Asthma Treatment Market, By Mode of Administration:

  • Inhalers
  • Nebulizers
  • Oral Medications

Asthma Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Asthma Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Asthma Treatment Market.

Available Customizations:

Global Asthma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Asthma Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Inhaled Corticosteroids (ICS), Leukotriene Modifiers, Immunomodulators, Combination Drugs, Others)
    • 5.2.2. By Mode of Administration (Inhalers, Nebulizers, Oral Medications)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Asthma Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Mode of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Asthma Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Mode of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Mexico Asthma Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Mode of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Canada Asthma Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Mode of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Asthma Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Mode of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Asthma Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Mode of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Germany Asthma Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Mode of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Asthma Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Mode of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Asthma Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Mode of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Asthma Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Mode of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Asthma Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Mode of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Asthma Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Mode of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Asthma Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Mode of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. South Korea Asthma Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Mode of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. Japan Asthma Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Mode of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Asthma Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Mode of Administration
        • 8.3.5.2.3. By Distribution Channel

9. South America Asthma Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Mode of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Asthma Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Mode of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Asthma Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Mode of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Asthma Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Mode of Administration
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Asthma Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Mode of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Asthma Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Mode of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Asthma Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Mode of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Asthma Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Mode of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. GlaxoSmithKline, Plc
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. AstraZeneca Plc
  • 14.3. Teva Pharmaceutical Industries Ltd.
  • 14.4. Boehringer Ingelheim Gmbh
  • 14.5. Merck & Co. Inc.
  • 14.6. Novartis AG
  • 14.7. Sanofi SA
  • 14.8. Roche Holding AG
  • 14.9. Regeneron Pharmaceutical Inc.
  • 14.10. Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer